Donor Lymphocyte Infusion (DLI) Volume and Dose Calculator
Calculates the CD3+ T-cell dose for donor lymphocyte infusion (DLI) in post-allogeneic HSCT relapse or mixed chimerism. DLI is used to induce graft-versus-leukaemia (GvL) effect. Starting dose for CML: 1 x 10^7 CD3+/kg. For AML/MDS: 1-5 x 10^7 CD3+/kg. Escalating dose protocol to minimise GvHD risk. Coordinated by transplant centre.
Score interpretation
DLI dose calculation complete -- transplant centre coordination required
→ ALL DLI infusions must be coordinated with the transplant centre (must be performed at JACIE-accredited centre or under transplant centre supervision); confirm donor availability and willingness for repeat donation (non-mobilised leukapheresis or unstimulated collection); chimerism studies must be reviewed before DLI decision; GvHD prophylaxis: no immunosuppression 2-4 weeks before DLI; pre-DLI bloods: FBC, renal, LFT, CMV, EBV viral load, chimerism; DLI administration: IV infusion over 15-30 minutes; monitor for GvHD for 3-6 months post-DLI; response assessment: chimerism and disease markers at 4-8 weeks post-DLI; document in BSBMT/EBMT registry.
Interpretation bands for the DLI Volume. Apply clinical judgement and local guidance.
References
- Kolb HJ et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990;76(12):2462-2465.
- JACIE/EBMT Standards. Hematopoietic Progenitor Cell Transplantation. European Group for Blood and Marrow Transplantation. 2022.
Related
Curated clinical cross-links plus same-class fallbacks.
- Dopamine (ICU — Vasopressor/Inotrope) · Catecholamine (Dose-Dependent Vasopressor/Inotrope)
- Potassium Chloride (IV) · Electrolyte — Potassium Supplement
- Insulin (IV Infusion — ICU Glucose Control) · Insulin — ICU Glucose Management
- Hydroxocobalamin (High-Dose — Cyanide Antidote) · Cyanide Antidote (Vitamin B12 Precursor at High Dose)
- Sodium Nitroprusside · Vasodilator — Nitric Oxide Donor (IV)
- Dopamine hydrochloride · Inotrope / vasopressor (dose-dependent)
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.